Bait Bakfar Ltd (BKFR) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Bait Bakfar Ltd ILS 9.75, price ILS 14.04, upside -30.6%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Bait Bakfar Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
56‑month range 7.38 ILA – 19.95 ILA · fair‑value band 7.00 ILA – 12.54 ILA · the 14.04 ILA price screens above the 9.75 ILA fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow Bait Bakfar in your weekly email
Every Wednesday you see whether Bait Bakfar is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Bait Bakfar Ltd manages and operates assisted living networks in Israel. The company offers health, welfare, and leisure services for the elderly population. Bait Bakfar Ltd was founded in 1988 is based in Kfar Saba, Israel.
Stock analysis
Bait Bakfar Ltd (BKFR) currently trades at 14.04 ILA, while our model-based Fair Value estimate is 9.75 ILA, implying the stock looks roughly 44.0% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 28.47 ILA per share, and 8 of the 26 models we run sit above the 14.04 ILA price.
Bear case: the Economic Profit group reads lowest at 1.70 ILA, and 18 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: 7.00 ILA (bear) to 12.54 ILA (bull), the price of 14.04 ILA sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Bait Bakfar Ltd reported revenue of 110M ILS in FY2025 versus 85.4M ILS in FY2021, a compound +6.4%/yr. Reported net income was 107M ILS in FY2025, compounding +18.1%/yr from FY2021.
Key figures
Market cap 982M ILA · P/E ratio 8.3 · P/S ratio 8.04 · EPS (TTM) 1.70 ILA · Dividend yield 3.1% · Net margin 97.4% · Return on equity 10.1% · Return on assets (EBIT) 6.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 15% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −31%, BKFR screens richer than that median.
Fair Value models
Bear 7.00 ILAFair Value 9.75 ILABull 12.54 ILA
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.9325 ILS per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.75/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+6.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.0%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+17.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+14.1%
Dividend (yield on the price)3.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.51% → 41%
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+6.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Israel: IMF forecast 2.1% a year to 2030, 1.7% from 2016 to 2025) that is about +4.7% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 258 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside−32% · Below median
Profitability
Return on equity (TTM)10% · Above median
Return on assets1% · Below median
Net margin (TTM)107% · Top 25%
Operating margin (TTM)38% · Top 25%
Growth and dividend
Revenue growth9% · Above median
Dividend yield (TTM)3.1% · Above median
Balance sheet
Debt / equity0.08× · Below median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (TTM)8.3× · Cheapest 25%
P/B0.26× · Cheapest 25%
P/S (TTM)2.92× · Priciest 25%
P/FCF5.1× · Pricier than median
EV/EBITDA8.9× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 33
FUTURE (revenue growth)43· sector 28
PAST (return on equity)41· sector 31
HEALTH (low debt)96· sector 89
DIVIDEND (yield)61· sector 43
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Bait Bakfar Ltd (BKFR) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of 9.75 ILA versus a price of 14.04 ILA, about −31% upside (overvalued).
What is the fair value of BKFR?
Our model-based fair value for Bait Bakfar Ltd is 9.75 ILA (as of Sep 23, 2026), built from audited fundamentals. The current price: 14.04 ILA.
What is the quality score of BKFR?
Bait Bakfar Ltd has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bait Bakfar Ltd (BKFR)?
Our model-based price target is the fair value of 9.75 ILA (as of Sep 23, 2026) from 26 valuation models. Cautious scenario 7.00 ILA, optimistic scenario 12.54 ILA. It is a calculation from audited fundamentals, not an analyst target.
What is the Bait Bakfar Ltd stock forecast for 2026?
Our models put fair value at 9.75 ILA, about −31% upside versus a price of 14.04 ILA (overvalued). Cautious scenario 7.00 ILA, optimistic scenario 12.54 ILA. The calculation is refreshed regularly with new filings.
What is the revenue of Bait Bakfar Ltd (BKFR)?
Bait Bakfar Ltd reported trailing-twelve-month revenue of about 112M ILS (latest available figure, as of Sep 23, 2026).
Does Bait Bakfar Ltd pay a dividend?
Bait Bakfar Ltd currently shows a dividend yield of about 3.06% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Bait Bakfar Ltd (BKFR)?
For today's price to be fair in a discounted-cash-flow model, Bait Bakfar Ltd would have to grow free cash flow by +6.8 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.4 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of BKFR use?
Our models discount Bait Bakfar Ltd at 11.6 %: a base by market capitalisation (small), damped by beta 0.23, country premium for Israel. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Bait Bakfar Ltd that is +6.8 % per year a year over ten years, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Bait Bakfar Ltd (BKFR) delivered so far?
Over the past 5 years revenue at Bait Bakfar Ltd grew +5.4 % a year. The price currently implies +6.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Bait Bakfar Ltd (BKFR) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Bait Bakfar Ltd (+6.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Bait Bakfar Ltd (BKFR)?
The free-cash-flow yield on the price is 6.48 %: that much free cash flow Bait Bakfar Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Bait Bakfar Ltd (BKFR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bait Bakfar Ltd it is 9.75 ILA per share (as of Sep 23, 2026), against a price of 14.04 ILA. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Bait Bakfar Ltd stock overvalued or undervalued in 2026?
As of Sep 23, 2026, BKFR trades above its calculated fair value: price 14.04 ILA, fair value 9.75 ILA, a gap of about −31% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BKFR?
No. The price is what the market pays today (14.04 ILA); the fair value is what the company's own numbers justify (9.75 ILA). For Bait Bakfar Ltd the two are 4.29 ILA per share apart. That gap is exactly why we show both numbers side by side.
How much is Bait Bakfar Ltd worth?
The market values Bait Bakfar Ltd at about 982M ILA (market capitalisation, as of Sep 23, 2026). Per share that is 14.04 ILA; our models calculate a fair value of 9.75 ILA per share.
What do the bullish and bearish scenarios say about BKFR?
Our models span a range for Bait Bakfar Ltd: cautious scenario 7.00 ILA, base 9.75 ILA, optimistic 12.54 ILA per share (as of Sep 23, 2026, price 14.04 ILA). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BKFR?
Bait Bakfar Ltd trades at a price-to-earnings ratio of 8.3 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 9.75 ILA is built from several models across several years. Other multiples: P/B 0.3, P/S 2.9, EV/EBITDA 8.9.
How solid is the balance sheet of Bait Bakfar Ltd (BKFR)?
Balance-sheet figures for Bait Bakfar Ltd (as of Sep 23, 2026): return on equity 10.1%, debt of 0.08 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is BKFR from its 52-week high?
Bait Bakfar Ltd trades at 14.04 ILA, about 15% below its 52-week high of 16.61 ILA and 15% above the low of 12.23 ILA (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 9.75 ILA is for.
Which stocks are comparable to Bait Bakfar Ltd?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bait Bakfar Ltd stock attractive at the current price?
The data as of Sep 23, 2026: price 14.04 ILA, calculated fair value 9.75 ILA (−31%), Quality Score 52/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BKFR calculated?
We run Bait Bakfar Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 9.75 ILA, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Bait Bakfar Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bait Bakfar Ltd (BKFR)?
The closing price on Sep 24, 2026 was 14.04 ILA. Our model-based fair value is 9.75 ILA, about −31% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bait Bakfar Ltd right now?
The price sits above even our optimistic bull case (12.54 ILA). The favourable scenario is already priced in. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Bait Bakfar Ltd
How large is the market capitalisation of Bait Bakfar Ltd (BKFR)?
The market capitalisation of Bait Bakfar Ltd is 982M ILA. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bait Bakfar Ltd (BKFR)?
The price-to-sales ratio of Bait Bakfar Ltd is 8.04 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bait Bakfar Ltd (BKFR)?
Earnings per share at Bait Bakfar Ltd are 1.70 ILA (price ÷ EPS = P/E 8.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Bait Bakfar Ltd (BKFR)?
The dividend yield of Bait Bakfar Ltd is 3.1% (payout 25.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Bait Bakfar Ltd (BKFR)?
The net margin of Bait Bakfar Ltd is 97.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bait Bakfar Ltd (BKFR)?
The return on equity (ROE) of Bait Bakfar Ltd is 10.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bait Bakfar Ltd (BKFR)?
On an EBIT basis the return on assets of Bait Bakfar Ltd is 6.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bait Bakfar Ltd (BKFR)?
The operating margin of Bait Bakfar Ltd is 37.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bait Bakfar Ltd (BKFR)?
Revenue at Bait Bakfar Ltd is growing +8.6% versus a year earlier (3y avg +5.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bait Bakfar Ltd (BKFR)?
Earnings per share at Bait Bakfar Ltd are growing +200% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Bait Bakfar Ltd (BKFR) carry?
The net debt of Bait Bakfar Ltd is 86.8M ILA (fiscal year 2025, ≈ 1.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Bait Bakfar Ltd in the live analysis
One click puts Bait Bakfar Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
